Laura P Hurley1,2, Sean T O'Leary3,4, Kathleen Dooling5, Tara C Anderson5, Lori A Crane3,6, Jessica R Cataldi3,4, Michaela Brtnikova3,4, Brenda L Beaty3, Carol Gorman3, Angela Guo5,7, Megan C Lindley5, Allison Kempe3,4. 1. Adult and Child Consortium for Health Outcomes Research and Delivery Science, University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, CO, USA. Laura.Hurley@dhha.org. 2. Division of General Internal Medicine, Denver Health, Denver, CO, USA. Laura.Hurley@dhha.org. 3. Adult and Child Consortium for Health Outcomes Research and Delivery Science, University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, CO, USA. 4. Department of Pediatrics University of Colorado Anschutz Medical Center, Aurora, CO, USA. 5. National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. 6. Department of Community and Behavioral Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 7. Strategic Innovative Solutions, LLC, Atlanta, GA, USA.
Abstract
BACKGROUND: Herpes zoster vaccination rates remain low despite longstanding national recommendations to vaccinate immunocompetent adults aged ≥ 50 years. The Advisory Committee on Immunization Practice (ACIP) updated its recommendations for recombinant zoster vaccine (RZV) in October 2021 to include immunocompromised adults aged ≥19 years. OBJECTIVE: To assess practices, attitudes, and knowledge about RZV, barriers to recommending RZV, and likelihood of recommending RZV to patients with various immunocompromising conditions. DESIGN: Mail and internet-based survey conducted from May through July 2020. PARTICIPANTS: General internists and family physicians throughout the USA. MAIN MEASURES: Survey responses. KEY RESULTS: The response rate was 66% (632/955). Many physicians were already recommending RZV to immunocompromised populations, including adults ≥50 years with HIV (67% of respondents) and on recombinant human immune modulator therapy (56%). Forty-seven percent of respondents both stocked/administered RZV and referred patients elsewhere, frequently a pharmacy, for vaccination; 42% did not stock RZV and only referred patients. The majority agreed pharmacies do not inform them when RZV has been given (64%). Physicians were generally knowledgeable about RZV; however, 25% incorrectly thought experiencing side effects from the first dose of RZV that interfere with normal activities was a reason to not receive the second dose. The top reported barrier to recommending RZV was experience with patients declining RZV due to cost concerns (67%). Most physicians reported they would be likely to recommend RZV to immunocompromised patients. CONCLUSION: Most primary care physicians welcome updated ACIP RZV recommendations for immunocompromised adults. Knowledge gaps, communication issues, and financial barriers need to be addressed to optimize vaccination delivery.
BACKGROUND: Herpes zoster vaccination rates remain low despite longstanding national recommendations to vaccinate immunocompetent adults aged ≥ 50 years. The Advisory Committee on Immunization Practice (ACIP) updated its recommendations for recombinant zoster vaccine (RZV) in October 2021 to include immunocompromised adults aged ≥19 years. OBJECTIVE: To assess practices, attitudes, and knowledge about RZV, barriers to recommending RZV, and likelihood of recommending RZV to patients with various immunocompromising conditions. DESIGN: Mail and internet-based survey conducted from May through July 2020. PARTICIPANTS: General internists and family physicians throughout the USA. MAIN MEASURES: Survey responses. KEY RESULTS: The response rate was 66% (632/955). Many physicians were already recommending RZV to immunocompromised populations, including adults ≥50 years with HIV (67% of respondents) and on recombinant human immune modulator therapy (56%). Forty-seven percent of respondents both stocked/administered RZV and referred patients elsewhere, frequently a pharmacy, for vaccination; 42% did not stock RZV and only referred patients. The majority agreed pharmacies do not inform them when RZV has been given (64%). Physicians were generally knowledgeable about RZV; however, 25% incorrectly thought experiencing side effects from the first dose of RZV that interfere with normal activities was a reason to not receive the second dose. The top reported barrier to recommending RZV was experience with patients declining RZV due to cost concerns (67%). Most physicians reported they would be likely to recommend RZV to immunocompromised patients. CONCLUSION: Most primary care physicians welcome updated ACIP RZV recommendations for immunocompromised adults. Knowledge gaps, communication issues, and financial barriers need to be addressed to optimize vaccination delivery.
Authors: Robert H Dworkin; Robert W Johnson; Judith Breuer; John W Gnann; Myron J Levin; Miroslav Backonja; Robert F Betts; Anne A Gershon; Maija L Haanpaa; Michael W McKendrick; Turo J Nurmikko; Anne Louise Oaklander; Michael N Oxman; Deborah Pavan-Langston; Karin L Petersen; Michael C Rowbotham; Kenneth E Schmader; Brett R Stacey; Stephen K Tyring; Albert J M van Wijck; Mark S Wallace; Sawko W Wassilew; Richard J Whitley Journal: Clin Infect Dis Date: 2007-01-01 Impact factor: 9.079
Authors: Lori A Crane; Matthew F Daley; Jennifer Barrow; Christine Babbel; Shannon Stokley; L Miriam Dickinson; Brenda L Beaty; John F Steiner; Allison Kempe Journal: Eval Health Prof Date: 2008-01-08 Impact factor: 2.651
Authors: Adriana Bastidas; Javier de la Serna; Mohamed El Idrissi; Lidia Oostvogels; Philippe Quittet; Javier López-Jiménez; Filiz Vural; David Pohlreich; Tsila Zuckerman; Nicolas C Issa; Gianluca Gaidano; Je-Jung Lee; Sunil Abhyankar; Carlos Solano; Jaime Perez de Oteyza; Michael J Satlin; Stefan Schwartz; Magda Campins; Alberto Rocci; Carlos Vallejo Llamas; Dong-Gun Lee; Sen Mui Tan; Anna M Johnston; Andrew Grigg; Michael J Boeckh; Laura Campora; Marta Lopez-Fauqued; Thomas C Heineman; Edward A Stadtmauer; Keith M Sullivan Journal: JAMA Date: 2019-07-09 Impact factor: 56.272
Authors: Alemnew F Dagnew; Osman Ilhan; Won-Sik Lee; Dariusz Woszczyk; Jae-Yong Kwak; Stella Bowcock; Sang Kyun Sohn; Gabriela Rodriguez Macías; Tzeon-Jye Chiou; Dimas Quiel; Mickael Aoun; Maria Belen Navarro Matilla; Javier de la Serna; Samuel Milliken; John Murphy; Shelly A McNeil; Bruno Salaun; Emmanuel Di Paolo; Laura Campora; Marta López-Fauqued; Mohamed El Idrissi; Anne Schuind; Thomas C Heineman; Peter Van den Steen; Lidia Oostvogels Journal: Lancet Infect Dis Date: 2019-08-06 Impact factor: 25.071
Authors: Edward A Stadtmauer; Keith M Sullivan; Mohamed El Idrissi; Bruno Salaun; Aránzazu Alonso Alonso; Charalambos Andreadis; Veli-Jukka Anttila; Adrian Jc Bloor; Raewyn Broady; Claudia Cellini; Antonio Cuneo; Alemnew F Dagnew; Emmanuel Di Paolo; HyeonSeok Eom; Ana Pilar González-Rodríguez; Andrew Grigg; Andreas Guenther; Thomas C Heineman; Isidro Jarque; Jae-Yong Kwak; Alessandro Lucchesi; Lidia Oostvogels; Marta Polo Zarzuela; Anne E Schuind; Thomas C Shea; Ulla Marjatta Sinisalo; Filiz Vural; Lucrecia Yáñez San Segundo; Pierre Zachée; Adriana Bastidas Journal: Hum Vaccin Immunother Date: 2021-08-18 Impact factor: 3.452